Mechanical Unloading Promotes Myocardial Energy Recovery in Human Heart Failure

Background—Impaired bioenergetics is a prominent feature of the failing heart, but the underlying metabolic perturbations are poorly understood. Methods and Results—We compared metabolomic, gene transcript, and protein data from 6 paired samples of failing human left ventricular tissue obtained during left ventricular assist device insertion (heart failure samples) and at heart transplant (post-left ventricular assist device samples). Nonfailing left ventricular wall samples procured from explanted hearts of patients with right heart failure served as novel comparison samples. Metabolomic analyses uncovered a distinct pattern in heart failure tissue: 2.6-fold increased pyruvate concentrations coupled with reduced Krebs cycle intermediates and short-chain acylcarnitines, suggesting a global reduction in substrate oxidation. These findings were associated with decreased transcript levels for enzymes that catalyze fatty acid oxidation and pyruvate metabolism and for key transcriptional regulators of mitochondrial metabolism and biogenesis, peroxisome proliferator-activated receptor &ggr; coactivator 1&agr; (PGC1A, 1.3-fold) and estrogen-related receptor &agr; (ERRA, 1.2-fold) and &ggr; (ERRG, 2.2-fold). Thus, parallel decreases in key transcription factors and their target metabolic enzyme genes can explain the decreases in associated metabolic intermediates. Mechanical support with left ventricular assist device improved all of these metabolic and transcriptional defects. Conclusions—These observations underscore an important pathophysiologic role for severely defective metabolism in heart failure, while the reversibility of these defects by left ventricular assist device suggests metabolic resilience of the human heart.

[1]  S. Sihag,et al.  PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart. , 2009, Journal of molecular and cellular cardiology.

[2]  Colin Simpson,et al.  Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003: A Population Study of 5.1 Million People , 2009, Circulation.

[3]  Xianlin Han,et al.  The transcriptional coactivator PGC-1alpha is essential for maximal and efficient cardiac mitochondrial fatty acid oxidation and lipid homeostasis. , 2008, American journal of physiology. Heart and circulatory physiology.

[4]  Inger Ekman,et al.  Population Impact of Heart Failure and the Most Common Forms of Cancer: A Study of 1 162 309 Hospital Cases in Sweden (1988 to 2004) , 2010, Circulation. Cardiovascular quality and outcomes.

[5]  I. T. de Almeida,et al.  Carnitine palmitoyltransferase 2: New insights on the substrate specificity and implications for acylcarnitine profiling. , 2010, Biochimica et biophysica acta.

[6]  Stefan Neubauer,et al.  The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.

[7]  R. Naviaux,et al.  ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. , 2007, Cell metabolism.

[8]  Yuan-Tsong Chen,et al.  ENU mutagenesis identifies mice with mitochondrial branched-chain aminotransferase deficiency resembling human maple syrup urine disease. , 2004, The Journal of clinical investigation.

[9]  D. Glower,et al.  Metabolomic Profiling Reveals Distinct Patterns of Myocardial Substrate Use in Humans With Coronary Artery Disease or Left Ventricular Dysfunction During Surgical Ischemia/Reperfusion , 2009, Circulation.

[10]  Pim van der Harst,et al.  Telomere biology in healthy aging and disease , 2009, Pflügers Archiv - European Journal of Physiology.

[11]  P. D. del Nido,et al.  Impaired Mitochondrial Biogenesis Precedes Heart Failure in Right Ventricular Hypertrophy in Congenital Heart Disease , 2011, Circulation. Heart failure.

[12]  P. Buttrick,et al.  Reverse Remodeling With Left Ventricular Assist Devices: A Review of Clinical, Cellular, and Molecular Effects , 2011, Circulation. Heart failure.

[13]  Olga Ilkayeva,et al.  Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. , 2008, Cell metabolism.

[14]  S. Russell,et al.  Advanced heart failure treated with continuous-flow left ventricular assist device. , 2009, The New England journal of medicine.

[15]  Céline Guilbeau-Frugier,et al.  p53-PGC-1α pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice. , 2013, Antioxidants & redox signaling.

[16]  L. Chin,et al.  Telomere dysfunction induces metabolic and mitochondrial compromise , 2011, Nature.

[17]  H. Taegtmeyer,et al.  Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate. , 1991, The Journal of clinical investigation.

[18]  Svati H Shah,et al.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. , 2009, Cell metabolism.

[19]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[20]  N. Samani,et al.  Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study , 2007, The Lancet.

[21]  H. McDaniel,et al.  Glutamic dehydrogenase from rat heart mitochondria. II. Kinetic characteristics. , 1984, Journal of molecular and cellular cardiology.

[22]  N. de Jonge,et al.  Proteomic profiling of the human failing heart after left ventricular assist device support. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  I. Komuro,et al.  p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload , 2007, Nature.

[24]  Elizabeth Murphy,et al.  The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. , 2007, Cell metabolism.

[25]  David Millington,et al.  Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance , 2004, Nature Medicine.

[26]  Claire Redin,et al.  A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila, and Humans , 2012, Science.

[27]  I. Komuro,et al.  Ca2+/Calmodulin-Dependent Kinase II&dgr; Causes Heart Failure by Accumulation of p53 in Dilated Cardiomyopathy , 2010, Circulation.

[28]  N. Silverman,et al.  Abnormal mitochondrial respiration in failed human myocardium. , 2000, Journal of molecular and cellular cardiology.

[29]  Rick B. Vega,et al.  Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart. , 2013, Biochimica et biophysica acta.

[30]  D. Kelly,et al.  The PGC-1 cascade as a therapeutic target for heart failure. , 2011, Journal of molecular and cellular cardiology.

[31]  Torsten Doenst,et al.  PGC-1&bgr; Deficiency Accelerates the Transition to Heart Failure in Pressure Overload Hypertrophy , 2011, Circulation research.

[32]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Jensen,et al.  Compensatory responses to pyruvate carboxylase suppression in islet beta-cells. Preservation of glucose-stimulated insulin secretion. , 2006, The Journal of biological chemistry.

[34]  G. Couper,et al.  Defective DNA Replication Impairs Mitochondrial Biogenesis In Human Failing Hearts , 2010, Circulation research.

[35]  H. Taegtmeyer,et al.  Pyruvate carboxylation prevents the decline in contractile function of rat hearts oxidizing acetoacetate. , 1991, The American journal of physiology.

[36]  H. McDaniel,et al.  Conditions for glutamate dehydrogenase activity in heart mitochondria. , 1993, Biochemical medicine and metabolic biology.

[37]  O. Frazier,et al.  Metabolic Gene Expression in Fetal and Failing Human Heart , 2001, Circulation.

[38]  Leif E. Peterson,et al.  Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator–Activated Receptor γ in Cardiac Fibrosis , 2008, Diabetes.

[39]  S. Nagueh,et al.  Imaging for Ventricular Function and Myocardial Recovery on Nonpulsatile Ventricular Assist Devices , 2012, Circulation.

[40]  H A Krebs,et al.  Utilization of energy-providing substrates in the isolated working rat heart. , 1980, The Biochemical journal.

[41]  Dean Y. Li,et al.  Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action , 2011, Current opinion in cardiology.

[42]  O. Frazier,et al.  Downregulation of Metabolic Gene Expression in Failing Human Heart before and after Mechanical Unloading , 2002, Cardiology.

[43]  Magdi H. Yacoub,et al.  Reversal of Severe Heart Failure With a Continuous-Flow Left Ventricular Assist Device and Pharmacological Therapy: A Prospective Study , 2011, Circulation.

[44]  M. Blasco,et al.  Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation , 2003, The EMBO journal.

[45]  J. Cleveland,et al.  Incomplete Recovery of Myocyte Contractile Function Despite Improvement of Myocardial Architecture With Left Ventricular Assist Device Support , 2011, Circulation. Heart failure.

[46]  Ò. Miró,et al.  Mitochondrial function in heart muscle from patients with idiopathic dilated cardiomyopathy. , 2000, Cardiovascular research.

[47]  A. Garnier,et al.  Control by Circulating Factors of Mitochondrial Function and Transcription Cascade in Heart Failure: A Role for Endothelin-1 and Angiotensin II , 2009, Circulation. Heart failure.

[48]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .